Sveikiname prisijungus prie Roche Foundation Medicine interneto svetainės.

Šioje svetainėje nepateikiama medicininių patarimų ir (arba) gydymo nurodymų. Ji sukurta Foundation Medicine partnerės bendrovės Roche, todėl išsami informacija pateikiama anglų kalba.

Pasirinkite tinkamą skiltį:

Menu
Close
Our portfolioFoundationOne CDxFoundationOne®Liquid CDx FoundationOne Heme

 

 

Our portfolio
 

High-quality portfolio

A portfolio of extensively validated comprehensive profiling services to guide treatment and research decisions at optimal times beneficial to your patients' journeys

Foundation Medicine's portfolio of extensively validated comprehensive genomic profiling services provides powerful insights to guide efficient, personalised treatment decisions at optimal t imes beneficial to your patients' journeys:1-8
Solid tumourHaematologic malignancy andsarcomaWhattype of tumour does your patient have?Tissue sampleBlood sampleTissue-based test for solid tumours1,2Liquid biopsy test for solid tumours4,5Test for haematological malignancies and sarcomas7,8
EXLORE EXLORE
EXLORE EXLORE
EXLORE EXLORE
All our services use our leading comprehensive genomic profiling approach to identify clinically relevant alterations and potentially expand treatment options

All of Foundation Medicine's services use our leading comprehensive genomic profiling approach, wich broadly analyses the tumour genome to identify clinically relevant alterations and potentially expands patients' treatment options.1,2,4,5,7-13
Learn more about comprehensive genomic profilling
Genomic database

 

As our understanding of cancer evolves, so do our tests

Our continuously growing genomic database currently includes over 400,000 genomic profiles in over 150 common and rare tumour subtypes. Advanced bioinformatics interpret the data, including rare and complex alterations, to generate powerful insights.14 Our tests are constantly evolving to capture the most clinically relevant genomic alterations so you stay up-to-date and the latest treatment options can be considered.1,2,4,5

As our understanding of cancer evolves, so do our tests
References
  1. Frampton GM et al. Nat Biotechnol 2013; 31: 1023–1031.
  2. FoundationOne®CDx Technical Specifications, 2018. Available at: www.rochefoundationmedicine.com/f1cdxtech (Accessed March 2019).
  3. FoundationOne®CDx FDA Approval, 2017. Available at: https://www.accessdata.fda.gov/cdrh_docs/pdf17/P170019a.pdf (Accessed March 2019).
  4. Data on file: FoundationOne Liquid CDx Technical Specifications, 2020. Available at: http://www.eifu.online/FMI/190070862 (Accessed August 2020).
  5. Data on file: Clinical and analytical validation data file for FoundationOne Liquid CDx.
  6. FoundationOne Liquid CDx FDA Approval, 2020. Available at: https://www.foundationmedicine.com/press-releases/445c1f9e-6cbb-488b-84ad-5f133612b721 (Accessed August 2020).
  7. FoundationOne®Heme Technical Specifications, 2017. Available at: www.foundationmedicine.com/genomic-testing/foundation-one-heme (Accessed March 2019).
  8. He J et al. Blood 2016; 127: 3004–3014.
  9. Drilon A et al. Clin Cancer Res 2015; 21: 3631–3639.
  10. Rankin A et al. Oncologist 2016; 21: 1306–1314.
  11. Ross JS et al. Cancer 2016; 122: 2654–2662.
  12. Suh JH et al. Oncologist 2016; 21: 684–691.
  13. Hirshfield KM et al. Oncologist 2016; 21: 1315–1325.
  14. Foundation Insights. Available at: https://www.foundationmedicine.com/insights-and-trials/foundation-insights (Accessed March 2019).